2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Apoptosis, Pathogenesis, Genomics, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

4991 Functional characterization of patient-derived STAT3 mutations from large granular lymphocyte leukemia using a primary human T cell model

Zeguela Kamagate, MS, Thomas P Loughran, MD2, Danielle Cook, PhD3, Su-Fern Tan, PhD4, David J Feith, PhD5
1 University of Virginia, Charlottesville, Virginia, United States
2 University of Virginia, Charlottesville, Virginia, United States
3 University of Virginia, Charlottesville, Virginia, United States
4 University of Virginia, Charlottesville, Virginia, United States
5 University of Virginia, Charlottesville, Virginia, United States

Introduction: Large granular lymphocyte leukemia (LGLL) is a chronic lymphoproliferative disorder characterized by the clonal expansion of cytotoxic T cells or natural killer cells. Somatic activating mutations in STAT3 occur in more than 50% of patients and are associated with distinct clinical phenotypes; however, their mutation-specific mechanisms and functional consequences remain incompletely defined. Mechanistic studies have been limited by the lack of systems that isolate the effects of individual STAT3 mutations within an isogenic and physiologically relevant T cell context.

Methods: To address this limitation, we generated an EF1α promoter-driven lentiviral vector system to express wild-type (WT) or mutant STAT3 fused to a C-terminal Strep-tagII epitope (to distinguish vector-derived STAT3) and a P2A-linked truncated CD19 reporter (to enable enrichment of transduced cells). A panel of twelve patient-derived LGLL-associated STAT3 mutations spanning the coiled-coil, DNA-binding, and SH2 domains was first functionally screened in HEK293 cells. STAT3 phosphorylation was evaluated by immunoblotting for Y705 phosphorylation, and transcriptional activity was quantified using a STAT3-responsive luciferase reporter normalized to a constitutively expressed Renilla control. Selected activating STAT3 mutants spanning the coiled-coil, DNA-binding, and SH2 domains, identified through the HEK293 functional screen, were subsequently evaluated in primary human T cells. Primary human T cells were activated using anti-CD3/CD28 beads, transduced with lentiviral STAT3 constructs, enriched by CD19 selection, and expanded for up to two weeks in ImmunoCult medium supplemented with IL-2. Cell expansion and proliferation were assessed by cell counts throughout culture, while T cell memory differentiation was evaluated by flow cytometry using CD45RA and CD62L surface markers. STAT3 activation was evaluated by measuring Y705 phosphorylation by flow cytometry following IL-21 stimulation. Initial CUT&Tag experiments were performed using WT-expressing T cells with and without IL-21 stimulation to establish a workflow for profiling STAT3 genomic occupancy following cytokine activation.

Results: Functional screening in HEK293 cells identified multiple activating STAT3 mutants exhibiting increased Y705 phosphorylation and transcriptional reporter activity relative to WT, including variants outside the frequently mutated SH2 domain. Based on these findings, WT and the most common activating mutant, Y640F, were selected for initial characterization in the normal primary T cell model. Following enrichment of CD19-positive transduced cells, WT and Y640F-expressing populations reached approximately 98% and 88% purity, respectively. Upon IL-21 stimulation, Y640F-expressing T cells exhibited increased STAT3 phosphorylation compared with WT. Over time, Y640F cells demonstrated reduced expansion and increased differentiation toward effector memory and terminal effector memory (TEMRA) phenotypes, whereas WT cells maintained a larger naïve population and greater proliferative capacity. Initial CUT&Tag analysis in WT-expressing T cells identified promoter-enriched STAT3 binding following IL-21 stimulation with pathway enrichment for genes involved in lymphocyte differentiation, αβ T cell activation and differentiation, regulation of T cell activation, and leukocyte immune activation. Ongoing studies will confirm initial observations of Y640F-driven TEMRA differentiation and extend readouts to additional activating mutants to define mutation-specific mechanisms relevant to LGLL pathogenesis.

Conclusions: These findings demonstrate that LGLL-associated STAT3 mutations modulate functionally distinct signaling. Our integrated HEK293 screening and primary human T cell models provide a physiologically relevant system to compare patient-derived STAT3 mutations and investigate their effects on STAT3 activity, T cell differentiation, protein-protein interactions and chromatin occupancy.

Zeguela Kamagate, MS: No relevant conflicts of interest to declare.